Ralph Moss on Cancer--Expert Guidance for Crucial Decisions

SEARCH THIS SITE

CLINICAL TRIALS UNDERWAY (AS OF 5/98)
WITH ANTI-ANGIOGENIC DRUGS

NOTE: This listing does not imply an endorsement by us of clinical trials for cancer patients. But some people do wish to participate in such trials, and so we are providing this list as a public service. For more information on these trials speak to your oncologist or call the National Cancer Institute at 1-800-4-CANCER. For information on The Moss Reports call 718-636-4433.

1. Phase I Study of Carboxyamidotriazole Modulated by Ketoconazole in Patients with Advanced Malignancies

2. Phase II Study of CAI in Patients with Refractory or Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

3. Phase II Randomized Study of Oral Thalidomide in Hormone-Refractory Adenocarcinoma of the Prostate

4. Phase II Study of Oral Carboxyamidotriazole in Patients with Androgren-Independent Prostate Cancer

5. Phase II Study of Suramin for Metastatic Melanoma

6. Phase II Randomized Study of Oral Thalidomide in Metastatic Breast Cancer

7. Phase II Study of Oral Thalidomide in HIV-Associated Kaposi's Sarcoma

8. Phase I Study of Oral COL-3 in Patients with Refractory Metastatic Solid Tumors or Lymphoma

9. Phase II Pilot Study of Suramin for Refractory or Relapsed Multiple Myeloma and Castleman's Disease

10. Phase I/II Pilot Study of Interleukin-12 for AIDS-Associated Kaposi's Sarcoma

11. Phase II Study of Suramin for Recurrent Primary Adult Brain Tumors

12. Phase II Study of Suramin in Advanced Nonsmall Cell Lung Cancer

13. Phase II Study of TNP-470 for Advanced or Recurrent Squamous Cell Carcinoma of the Cervix

14. Phase III Randomized Study of Marimastat versus Placebo in Patients with Metastatic Breast Cancer Who Have Responding or Stable Disease After Induction Chemotherapy

15. Phase II Study of Suramin for Recurrent or Progressive Malignant Glioma

16. Phase I Study of Carboxyamidotriazole plus Paclitaxel for Advanced Solid Tumors and Refractory Lymphomas

17. Phase III Randomized Study of TNP-470 vs Synchronous Radiotherapy and 5-FU/CF for Locally Advanced Nonresectable Nonmetastatic Pancreatic Cancer

18. Phase I Study of Carboxyamidotriazole for Refractory Cancers

19. Phase I Study of TNP-470 in Patients with Recurrent or Refractory Pediatric Solid Tumors, Lymphomas, and Acute Leukemias

20. Phase III Randomized Study of Marimastat in Patients with Small Cell Lung Cancer following a Response to First Line Chemotherapy

Ralph W. Moss, Ph.D. is director of the The Moss Reports for cancer patients. Dr. Moss is the author of eleven books and three documentaries on cancer-related topics. He is or has been an advisor on alternative cancer treatments to the National Institutes of Health, the National Cancer Institute, the American Urological Association, Columbia University, the University of Texas, the Susan G. Komen Foundation and the German Society of Oncology. He wrote the first article on alternative medicine for the Encyclopedia Britannica yearbook. He is listed in Marquis Who's Who in America, Who's Who in the World, Who's Who in the East, and Who's Who in Entertainment (as a film documentarian). This Web site does not advocate any particular treatment for cancer. We urge you to always seek competent medical advice for all health problems, especially cancer. Before consulting our site please read our full Disclaimer statement.

CLINICAL TRIALS UNDERWAY (AS OF 5/98) WITH ANTI-ANGIOGENIC DRUGS

CLINICAL TRIALS UNDERWAY (AS OF 5/98)
WITH ANTI-ANGIOGENIC DRUGS